CN108210923A - 一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用 - Google Patents
一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用 Download PDFInfo
- Publication number
- CN108210923A CN108210923A CN201810091012.8A CN201810091012A CN108210923A CN 108210923 A CN108210923 A CN 108210923A CN 201810091012 A CN201810091012 A CN 201810091012A CN 108210923 A CN108210923 A CN 108210923A
- Authority
- CN
- China
- Prior art keywords
- seralbumin
- nanoparticle
- fluorescent dye
- brilliant blue
- coomassie brilliant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 74
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 65
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 title claims description 32
- 238000011282 treatment Methods 0.000 title description 8
- 238000003745 diagnosis Methods 0.000 title description 3
- 239000013067 intermediate product Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 10
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000006185 dispersion Substances 0.000 claims abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000002313 intestinal cancer Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- -1 Rhodamine B isothiocyanate Chemical class 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 5
- 239000000700 radioactive tracer Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 238000002679 ablation Methods 0.000 claims description 3
- 229940043267 rhodamine b Drugs 0.000 claims description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 238000007626 photothermal therapy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- IRPLSAGFWHCJIQ-UHFFFAOYSA-N selanylidenecopper Chemical compound [Se]=[Cu] IRPLSAGFWHCJIQ-UHFFFAOYSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810091012.8A CN108210923B (zh) | 2018-01-30 | 2018-01-30 | 一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810091012.8A CN108210923B (zh) | 2018-01-30 | 2018-01-30 | 一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108210923A true CN108210923A (zh) | 2018-06-29 |
CN108210923B CN108210923B (zh) | 2020-12-15 |
Family
ID=62669941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810091012.8A Active CN108210923B (zh) | 2018-01-30 | 2018-01-30 | 一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108210923B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111407897A (zh) * | 2020-03-26 | 2020-07-14 | 海南医学院 | 基于荧光染料与考马斯亮蓝共结合的亲和素纳米粒及其制备方法和在构建肿瘤疫苗中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103239737A (zh) * | 2013-04-27 | 2013-08-14 | 深圳先进技术研究院 | 荧光造影剂及其制备方法 |
CN105616384A (zh) * | 2016-03-08 | 2016-06-01 | 中国药科大学 | 一种包载紫杉醇的tpgs-还原性白蛋白纳米粒制剂及制备方法 |
WO2017214050A1 (en) * | 2016-06-08 | 2017-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of pancreatic cancer with an engineered anti-thy1 single-chain antibody |
-
2018
- 2018-01-30 CN CN201810091012.8A patent/CN108210923B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103239737A (zh) * | 2013-04-27 | 2013-08-14 | 深圳先进技术研究院 | 荧光造影剂及其制备方法 |
CN105616384A (zh) * | 2016-03-08 | 2016-06-01 | 中国药科大学 | 一种包载紫杉醇的tpgs-还原性白蛋白纳米粒制剂及制备方法 |
WO2017214050A1 (en) * | 2016-06-08 | 2017-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of pancreatic cancer with an engineered anti-thy1 single-chain antibody |
Non-Patent Citations (4)
Title |
---|
A.M. CHUAH ET AL: "Formation of Biocompatible Nanoparticles via the Self-Assembly of Chitosan and Modified Lecithin", 《JOURNAL OF FOOD SCIENCE》 * |
ZHUOXUAN LU ET AL: "Cy5.5-MSA-G250 nanoparticles (CMGNPs) induce M1 polarity of RAW264. 7 macrophage cells via TLR4-dependent manner", 《CHINESE CHEMICAL LETTERS》 * |
ZHUOXUAN LU ET AL: "Intrinsic, Cancer Cell-Selective Toxicity of Organic Photothermal Nanoagent: A Simple Formulation for Combined Photothermal Chemotherapy of Cancer", 《ACS APPL. MATER. INTERFACES》 * |
王永刚 等: "考马斯亮蓝G-250 与牛血清白蛋白的相互作用研究", 《现代食品科技》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111407897A (zh) * | 2020-03-26 | 2020-07-14 | 海南医学院 | 基于荧光染料与考马斯亮蓝共结合的亲和素纳米粒及其制备方法和在构建肿瘤疫苗中的应用 |
CN111407897B (zh) * | 2020-03-26 | 2023-01-31 | 海南医学院 | 基于荧光染料与考马斯亮蓝共结合的亲和素纳米粒及其制备方法和在构建肿瘤疫苗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108210923B (zh) | 2020-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Doxorubicin‐loaded single wall nanotube thermo‐sensitive hydrogel for gastric cancer chemo‐photothermal therapy | |
Liu et al. | Tumor-triggered drug release from calcium carbonate-encapsulated gold nanostars for near-infrared photodynamic/photothermal combination antitumor therapy | |
WO2015188570A1 (zh) | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 | |
US8323694B2 (en) | Gold nanoparticles for selective IR heating | |
CN107057398B (zh) | 一种七甲川菁荧光染料及其肿瘤精准诊断和治疗的应用 | |
CN104800845B (zh) | 一种具有肝癌细胞靶向性的二硫化钼载药纳米片的制备方法 | |
CN106512002B (zh) | 集ct成像与光疗于一体的多功能纳米杂化物及制备方法 | |
CN108219782A (zh) | 一种近红外荧光探针及基于该探针的多模态纳米造影剂及其制备和应用 | |
KR20170043862A (ko) | 종양 진단 및 치료용 나노입자 | |
CN105770893A (zh) | 一种铋基复合纳米材料及其肿瘤诊断与治疗应用 | |
CN105126113B (zh) | 一种转铁蛋白修饰的中空介孔硫化铜/青蒿琥酯纳米粒的制备方法及其应用 | |
Xuan et al. | Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes | |
He et al. | Paclitaxel/IR1061-co-loaded protein nanoparticle for tumor-targeted and pH/NIR-II-triggered synergistic photothermal-chemotherapy | |
WO2022112944A1 (en) | Nanosystem for diagnosis and photothermal treatment of tumors | |
Lee et al. | Synthesis, characterization, and biological evaluation of anti-her2 indocyanine green-encapsulated peg-coated plga nanoparticles for targeted phototherapy of breast cancer cells | |
CN105999267B (zh) | 二硫化钼纳米点/聚苯胺纳米杂化物及制备方法及应用 | |
Kim et al. | Upconverting nanoparticle-containing erythrocyte-sized hemoglobin microgels that generate heat, oxygen and reactive oxygen species for suppressing hypoxic tumors | |
CN109420181A (zh) | 一种用于肿瘤荧光成像及光热/光动力治疗的多功能纳米粒子 | |
Wang et al. | Recent progress toward imaging application of multifunction sonosensitizers in sonodynamic therapy | |
CN108578427A (zh) | 叶酸修饰的金纳米颗粒及其制备方法与在制备放射增敏治疗药物中的应用 | |
CN108210923A (zh) | 一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用 | |
CN104587466A (zh) | 蛋白-聚吡咯复合物及蛋白-聚吡咯复合物衍生物的制备方法与应用 | |
CN107303388B (zh) | 一种基于近红外染料-透明质酸复合物的诊断治疗制剂 | |
CN109589402A (zh) | 一种具有靶向光热治疗和可控释药的多重作用纳米材料的制备方法及应用 | |
Zhang et al. | Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Liming Inventor after: Lv Zhuoxuan Inventor after: Wang Dai Inventor after: Tan Guanghong Inventor after: Huang Fengying Inventor after: Cao Rong Inventor before: Zhang Liming Inventor before: Lv Zhuoxuan Inventor before: Tan Guanghong Inventor before: Huang Fengying Inventor before: Cao Rong |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |